This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC).
Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
This is a first-in-human, Phase 1, non-randomized, multicenter, open-label clinical study designed to investigate the safety, tolerability, dosimetry, biodistribution, and pharmacokinetics (PK) of \[225Ac\]-FPI-2068, \[111In\]-FPI-2107, and FPI-2053 in metastatic and/or recurrent solid tumors (HNSCC, NSCLC, mCRC, PDAC).
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients with Advanced Solid Tumours
-
Hoag Hospital, Irvine, California, United States, 92618
Stanford Hospital and Clinics, Stanford, California, United States, 94305
University of Chicago, Chicago, Illinois, United States, 60637
Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215
Washington University in St. Louis, St. Louis, Missouri, United States, 63110
Cleveland Clinic, Cleveland, Ohio, United States, 44195
UPMC Hillman Cancer Center Research Pavilion, Pittsburg, Pennsylvania, United States, 15213
MD Anderson Cancer Center, Houston, Texas, United States, 77030
University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States, 98109
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Fusion Pharmaceuticals Inc.,
Lorraine Hughes, MS, STUDY_DIRECTOR, Fusion Pharmaceuticals Inc.
2027-12-30